A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer
Introduction: Inflammatory breast cancer (IBC) is an uncommon, but aggressive form of breast cancer that accounts for a disproportionally high fraction of breast cancer related mortality. The aim of this study was to explore the peripheral immune response and the prognostic value of blood-based biom...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-10-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977620301594 |
| _version_ | 1828542855816151040 |
|---|---|
| author | C. Van Berckelaer M. Van Geyt S. Linders C. Rypens X.B. Trinh W.A.A. Tjalma S. Van Laere C. Colpaert L. Dirix P.A. van Dam |
| author_facet | C. Van Berckelaer M. Van Geyt S. Linders C. Rypens X.B. Trinh W.A.A. Tjalma S. Van Laere C. Colpaert L. Dirix P.A. van Dam |
| author_sort | C. Van Berckelaer |
| collection | DOAJ |
| description | Introduction: Inflammatory breast cancer (IBC) is an uncommon, but aggressive form of breast cancer that accounts for a disproportionally high fraction of breast cancer related mortality. The aim of this study was to explore the peripheral immune response and the prognostic value of blood-based biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), in a large IBC cohort. Patients & methods: We retrospectively identified 127 IBC patients and collected lab results from in-hospital medical records. The differential count of leukocytes was determined at the moment of diagnosis, before any therapeutic intervention. A cohort of early stage (n = 108), locally advanced (n = 74) and metastatic breast cancer patients (n = 41) served as a control population. Results: The NLR was significantly higher in IBC compared to an early stage breast cancer cohort, but no difference between IBC patients and locally advanced breast cancer patients was noted. In the metastatic setting, there was also no significant difference between IBC and nIBC. However, a high NLR (>4.0) remained a significant predictor of worse outcome in IBC patients (HR: 0.49; 95% CI: 0.24–1.00; P = .05) and a lower platelet-lymphocyte ratio (PLR) (≤210) correlated with a better disease-free survival (DFS) (HR: 0.51; 95% CI: 0.28–0.93; P = .03). Conclusion: Patients with a high NLR (>4.0) have a worse overall prognosis in IBC, while the PLR correlated with relapse free survival (RFS). Since NLR and PLR were not specifically associated with IBC disease, they can be seen as markers of more extensive disease. |
| first_indexed | 2024-12-12T02:04:35Z |
| format | Article |
| id | doaj.art-ef606cdc639946d6a9e119a8575a8dfe |
| institution | Directory Open Access Journal |
| issn | 1532-3080 |
| language | English |
| last_indexed | 2024-12-12T02:04:35Z |
| publishDate | 2020-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj.art-ef606cdc639946d6a9e119a8575a8dfe2022-12-22T00:42:06ZengElsevierBreast1532-30802020-10-0153212220A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancerC. Van Berckelaer0M. Van Geyt1S. Linders2C. Rypens3X.B. Trinh4W.A.A. Tjalma5S. Van Laere6C. Colpaert7L. Dirix8P.A. van Dam9Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium; Multidisciplinary Breast Clinic, Unit Gynaecologic Oncology, Antwerp University Hospital (UZA) (Belgium), Molecular Imaging, Pathology, Radiotherapy, Oncology (MIPRO), Faculty of Medicine and Health Sciences, University of Antwerp, Belgium; Corresponding author. Translational Cancer Research Unit, CORE, University of Antwerp Oosterveldlaan 24 2610, Antwerp, Belgium.Multidisciplinary Breast Clinic, Unit Gynaecologic Oncology, Antwerp University Hospital (UZA) (Belgium), Molecular Imaging, Pathology, Radiotherapy, Oncology (MIPRO), Faculty of Medicine and Health Sciences, University of Antwerp, BelgiumMultidisciplinary Breast Clinic, Unit Gynaecologic Oncology, Antwerp University Hospital (UZA) (Belgium), Molecular Imaging, Pathology, Radiotherapy, Oncology (MIPRO), Faculty of Medicine and Health Sciences, University of Antwerp, BelgiumTranslational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, BelgiumMultidisciplinary Breast Clinic, Unit Gynaecologic Oncology, Antwerp University Hospital (UZA) (Belgium), Molecular Imaging, Pathology, Radiotherapy, Oncology (MIPRO), Faculty of Medicine and Health Sciences, University of Antwerp, BelgiumMultidisciplinary Breast Clinic, Unit Gynaecologic Oncology, Antwerp University Hospital (UZA) (Belgium), Molecular Imaging, Pathology, Radiotherapy, Oncology (MIPRO), Faculty of Medicine and Health Sciences, University of Antwerp, BelgiumTranslational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, BelgiumDepartment of Pathology, UZA, Antwerp University Hospital, Edegem, BelgiumTranslational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium; Department of Oncology, GZA Hospitals Sint-Augustinus, Antwerp, BelgiumMultidisciplinary Breast Clinic, Unit Gynaecologic Oncology, Antwerp University Hospital (UZA) (Belgium), Molecular Imaging, Pathology, Radiotherapy, Oncology (MIPRO), Faculty of Medicine and Health Sciences, University of Antwerp, BelgiumIntroduction: Inflammatory breast cancer (IBC) is an uncommon, but aggressive form of breast cancer that accounts for a disproportionally high fraction of breast cancer related mortality. The aim of this study was to explore the peripheral immune response and the prognostic value of blood-based biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), in a large IBC cohort. Patients & methods: We retrospectively identified 127 IBC patients and collected lab results from in-hospital medical records. The differential count of leukocytes was determined at the moment of diagnosis, before any therapeutic intervention. A cohort of early stage (n = 108), locally advanced (n = 74) and metastatic breast cancer patients (n = 41) served as a control population. Results: The NLR was significantly higher in IBC compared to an early stage breast cancer cohort, but no difference between IBC patients and locally advanced breast cancer patients was noted. In the metastatic setting, there was also no significant difference between IBC and nIBC. However, a high NLR (>4.0) remained a significant predictor of worse outcome in IBC patients (HR: 0.49; 95% CI: 0.24–1.00; P = .05) and a lower platelet-lymphocyte ratio (PLR) (≤210) correlated with a better disease-free survival (DFS) (HR: 0.51; 95% CI: 0.28–0.93; P = .03). Conclusion: Patients with a high NLR (>4.0) have a worse overall prognosis in IBC, while the PLR correlated with relapse free survival (RFS). Since NLR and PLR were not specifically associated with IBC disease, they can be seen as markers of more extensive disease.http://www.sciencedirect.com/science/article/pii/S0960977620301594Inflammatory breast cancer (IBC)Neutrophil-to-lymphocyte ratio (NLR)Platelet-lymphocyte ratio (PLR)Lymphocyte-monocyte ratio (LMR)Stromal tumor infiltrating lymphocytes (sTIL)Immune response |
| spellingShingle | C. Van Berckelaer M. Van Geyt S. Linders C. Rypens X.B. Trinh W.A.A. Tjalma S. Van Laere C. Colpaert L. Dirix P.A. van Dam A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer Breast Inflammatory breast cancer (IBC) Neutrophil-to-lymphocyte ratio (NLR) Platelet-lymphocyte ratio (PLR) Lymphocyte-monocyte ratio (LMR) Stromal tumor infiltrating lymphocytes (sTIL) Immune response |
| title | A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer |
| title_full | A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer |
| title_fullStr | A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer |
| title_full_unstemmed | A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer |
| title_short | A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer |
| title_sort | high neutrophil lymphocyte ratio and platelet lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer |
| topic | Inflammatory breast cancer (IBC) Neutrophil-to-lymphocyte ratio (NLR) Platelet-lymphocyte ratio (PLR) Lymphocyte-monocyte ratio (LMR) Stromal tumor infiltrating lymphocytes (sTIL) Immune response |
| url | http://www.sciencedirect.com/science/article/pii/S0960977620301594 |
| work_keys_str_mv | AT cvanberckelaer ahighneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT mvangeyt ahighneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT slinders ahighneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT crypens ahighneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT xbtrinh ahighneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT waatjalma ahighneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT svanlaere ahighneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT ccolpaert ahighneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT ldirix ahighneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT pavandam ahighneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT cvanberckelaer highneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT mvangeyt highneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT slinders highneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT crypens highneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT xbtrinh highneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT waatjalma highneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT svanlaere highneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT ccolpaert highneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT ldirix highneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer AT pavandam highneutrophillymphocyteratioandplateletlymphocyteratioareassociatedwithaworseoutcomeininflammatorybreastcancer |